population has specific characteristics marked by a shorter life expectancy 
relative to community-dwelling older adults, high prevalence of multimorbidity 
with a high rate of complications, dementia, frailty, disability, and often 
polypharmacy. As a result, OD is associated with malnutrition, dehydration, 
aspiration pneumonia, functional decline, and death. Complications of OD can 
potentially be prevented with the use of TMDs.
RESULTS: This report presents expert opinion and evidence-informed 
recommendations for best practice on the nutritional management of OD. It aims 
to highlight the practice gaps between the evidence-based management of OD and 
real-world patterns, including inadequate dietary provision and insufficient 
staff training. In addition, the unmet need for OD screening and improvements in 
therapeutic diets are explored and discussed.
CONCLUSION: There is currently limited empirical evidence to guide practice in 
OD management. Given the complex and heterogeneous population of long-stay NH 
residents, some 'best practice' approaches and interventions require extensive 
efficacy testing before further changes in policy can be implemented.

DOI: 10.1007/s12603-020-1377-5
PMID: 32510109 [Indexed for MEDLINE]

Conflict of interest statement: Dr. Simmons reports personal fees from Nestlé 
Health Science, during the conduct of the study. Dr. Ballesteros-Pomar reports 
personal fees from Nestlé Health Science, during the conduct of the study. Dr. 
Cherubini reports personal fees from Nestlé Health Science, during the conduct 
of the study. Dr. Keller reports other from Nestlé Health Science during the 
conduct of the study; grants and other from Abbott Nutrition, outside the 
submitted work. Dr. Rolland reports grants from Biophytis, Novartis, outside the 
submitted work. Mr. Lam reports other from Nestlé Health Science, during the 
conduct of the study; other from International Dysphagia Diet Standardization 
Initiative, personal fees from Nestlé Health Science, outside the submitted 
work; and Co-chair of the International Dysphagia Diet Standardization 
Initiative.


573. J Hosp Palliat Nurs. 2020 Aug;22(4):260-269. doi:
10.1097/NJH.0000000000000665.

Recommendations to Leverage the Palliative Nursing Role During COVID-19 and 
Future Public Health Crises.

Rosa WE(1), Gray TF, Chow K, Davidson PM, Dionne-Odom JN, Karanja V, Khanyola J, 
Kpoeh JDN, Lusaka J, Matula ST, Mazanec P, Moreland PJ, Pandey S, de Campos AP, 
Meghani SH.

Author information:
(1)William E. Rosa, PhD, MBE, ACHPN, FAANP, FAAN, is Robert Wood Johnson 
Foundation Future of Nursing Scholar, University of Pennsylvania School of 
Nursing, Philadelphia. Tamryn F. Gray, PhD, RN, is research fellow, Department 
of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, 
Harvard Medical School, Boston, Massachusetts. Kimberly Chow, RN, ANP-BC, ACHPN, 
is nurse practitioner, Supportive Care Service, Memorial Sloan Kettering Cancer 
Center, New York. Patricia M. Davidson, PhD, RN, FAAN, is dean and professor, 
Johns Hopkins University School of Nursing, Baltimore, Maryland. J. Nicholas 
Dionne-Odom, PhD, MSN, MA, ACHPN, FPCN, is assistant professor, University of 
Alabama at Birmingham School of Nursing; and codirector, Caregiver and 
Bereavement Support Services, UAB Center for Palliative and Supportive Care. 
Viola Karanja, BSN, RN, is deputy executive director, Partners in Health 
Liberia, Harper. Judy Khanyola, MSc, RCHN, is Chair, Nursing and Midwifery, 
University of Global Health Equity, Butaro, Rwanda. Julius D. N. Kpoeh, ASN, RN, 
is senior clinical mentor, Partners in Health Liberia, Harper. Joseph Lusaka, 
BSc HM, DCM, PA, is clinical manager, Pleebo Health Centre, Liberia. Samuel T. 
Matula, PhD, RN, PCNS-BC, is lecturer, University of Botswana, Gaborone. Polly 
Mazanec, PhD, AOCN, ACHPN, FPCN, FAAN, is research associate professor, Frances 
Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, 
Ohio. Patricia J. Moreland, PhD, CPNP, FAAN, is assistant clinical professor, 
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia. 
Shila Pandey, MSN, AGPCNP-BC, ACHPN, is nurse practitioner, Supportive Care 
Service, Memorial Sloan Kettering Cancer Center, New York. Amisha Parekh de 
Campos, PhD, MPH, CHPN, Robert Wood Johnson Foundation Future of Nursing 
Scholar, University of Connecticut, Storrs; quality and education coordinator, 
Hospice Program, Middlesex Health, Connecticut. Salimah H. Meghani, PhD, MBE, 
RN, FAAN, is professor and term chair of Palliative Care, University of 
Pennsylvania School of Nursing, Philadelphia.

With the daily number of confirmed COVID-19 cases and associated deaths rising 
exponentially, social fabrics on a global scale are being worn by panic, 
uncertainty, fear, and other consequences of the health care crisis. Comprising 
more than half of the global health care workforce and the highest proportion of 
direct patient care time than any other health professional, nurses are at the 
forefront of this crisis. Throughout the evolving COVID-19 pandemic, palliative 
nurses will increasingly exercise their expertise in symptom management, ethics, 
communication, and end-of-life care, among other crucial skills. The literature 
addressing the palliative care response to COVID-19 has surged, and yet, there 
is a critical gap regarding the unique contributions of palliative nurses and 
their essential role in mitigating the sequelae of this crisis. Thus, the 
primary aim herein is to provide recommendations for palliative nurses and other 
health care stakeholders to ensure their optimal value is realized and to 
promote their well-being and resilience during COVID-19 and, by extension, in 
anticipation of future public health crises.

DOI: 10.1097/NJH.0000000000000665
PMCID: PMC8018720
PMID: 32511171 [Indexed for MEDLINE]

Conflict of interest statement: The authors have no conflicts of interest to 
disclose.


574. medRxiv. 2021 Jan 12:2020.04.29.20085506. doi: 10.1101/2020.04.29.20085506. 
Preprint.

Beyond Deaths per Capita: Comparative CoViD-19 Mortality Indicators.

Heuveline P(1), Tzen M(1).

Author information:
(1)California Center for Population Research (CCPR), University of California, 
Los Angeles (UCLA).

Update in
    BMJ Open. 2021 Mar 10;11(3):e042934.

OBJECTIVES: Following well-established practices in demography, this article 
discusses several measures based on the number of CoViD-19 deaths to facilitate 
comparisons over time and across populations.
SETTINGS: National populations in 186 UN countries and territories and 
populations in first-level sub-national administrative entities in Brazil, 
China, Italy, Mexico, Peru, Spain, and the USA.
PARTICIPANTS: None (death statistics only).
PRIMARY AND SECONDARY OUTCOME MEASURES: An unstandardized occurrence/exposure 
rate comparable to the Crude Death Rate; an indirectly age-and-sex standardized 
rate that can be derived even when the breakdown of CoViD-19 deaths by age and 
sex required for direct standardization is unavailable; the reduction in life 
expectancy at birth corresponding to the 2020 number of CoViD-19 deaths.
RESULTS: To date, the highest unstandardized rate has been in New York, at its 
peak exceeding the state 2017 Crude Death Rate. Populations compare differently 
after standardization: while parts of Italy, Spain and the USA have the highest 
unstandardized rates, parts of Mexico and Peru have the highest standardized 
rates. For several populations with the necessary data by age and sex for direct 
standardization, we show that direct and indirect standardization yield similar 
results. US life expectancy is estimated to have declined this year by more than 
a year (-1.26 years), far more than during the worst year of the HIV epidemic, 
or the worst three years of the opioid crisis, and to reach its lowest level 
since 2008. Substantially larger reductions, exceeding two years, are estimated 
for Panama, Peru, and parts of Italy, Spain, the USA, and especially, Mexico.
CONCLUSIONS: With lesser demand on data than direct standardization, indirect 
standardization is a valid alternative to adjust international comparisons for 
differences in population distribution by sex and age-groups. A number of 
populations have experienced reductions in 2020 life expectancies that are 
substantial by recent historical standards.

DOI: 10.1101/2020.04.29.20085506
PMCID: PMC7273293
PMID: 32511525


575. JAMA Netw Open. 2020 Jun 1;3(6):e206772. doi:
10.1001/jamanetworkopen.2020.6772.

Assessment of Clinician Decision-making on Cancer Screening Cessation in Older 
Adults With Limited Life Expectancy.

Schoenborn NL(1), Massare J(1), Park R(2), Boyd CM(1), Choi Y(1), Pollack CE(3).

Author information:
(1)Department of Medicine, Johns Hopkins University School of Medicine, 
Baltimore, Maryland.
(2)Department of Biology and Public Health, Johns Hopkins University, Baltimore, 
Maryland.
(3)Department of Health Policy and Management, Johns Hopkins Bloomberg School of 
Public Health, Johns Hopkins University, Baltimore, Maryland.

IMPORTANCE: Despite clinical practice guidelines recommending against routine 
cancer screening in older adults with limited life expectancy, older adults are 
still frequently screened for breast, colorectal, and prostate cancers.
OBJECTIVE: To examine primary care clinicians' decision-making on stopping 
breast, colorectal, or prostate cancer screening in older adults with limited 
life expectancy.
DESIGN, SETTING, AND PARTICIPANTS: In qualitative interviews coupled with 
medical record-stimulated recall, clinicians from 17 academic and community 
clinics affiliated with a large health system were asked how they came to 
specific cancer screening decisions in 2 or 3 of their older patients with less 
than 10-year of estimated life expectancy, including patients with and without 
recent screening. Patients were surveyed by telephone. Data collection occurred 
between October 2018 and May 2019.
MAIN OUTCOMES AND MEASURES: Clinician interviews were audio-recorded and 
transcribed verbatim. Transcripts were analyzed with qualitative content 
analysis to identify major themes. Patient surveys assessed perception of cancer 
screening decisions, importance of clinician recommendation, and willingness to 
stop screening.
RESULTS: Twenty-five primary care clinicians (mean [SD] age, 47.1 [9.7] years; 
14 female [56%]) discussed 53 patients during medical record-stimulated recall, 
ranging from 2 to 3 patients per clinician; 46 patients and 1 caregiver (mean 
[SD] age 74.9 [5.4]; 31 female [66%]) participated in the survey. Clinician 
interviews revealed 5 major themes: (1) cancer screening decisions were not 
always conscious, deliberate decisions; (2) electronic medical record alerts 
were connected with less deliberate decision-making; (3) cancer screening was 
not binary and clinicians often considered other options to scale back screening 
without actually stopping; (4) in addition to patient characteristics, 
clinicians were influenced by patient request and anecdotal experiences; and (5) 
influences outside of the primary care clinician-patient dyad were important, 
such as from specialists and patients' family or friends. Patient surveys asked 
approximately 64 cancer screening decisions of 47 patients. Patients did not 
recall approximately half (31 of 64) of their cancer screening decisions. Among 
those with recent screening, the mean score for willingness to stop screening 
was 3.2 (95% CI 2.5-3.9) on a 5-point Likert scale (with 1 indicating "extremely 
unlikely" and 5 indicating "extremely likely"). In most screening decisions that 
involved specialists (13 of 16), patients valued specialists' recommendations 
over those of primary care clinicians.
CONCLUSIONS AND RELEVANCE: Cancer screening decision-making is complex. Study 
findings suggest that strategies that facilitate more deliberate decision-making 
may be important in cancer screening of older adults with limited life 
expectancy.

DOI: 10.1001/jamanetworkopen.2020.6772
PMCID: PMC7280953
PMID: 32511720 [Indexed for MEDLINE]

Conflict of interest statement: Conflict of Interest Disclosures: Dr Schoenborn 
reported receiving grants from the National Institute on Aging during the 
conduct of the study. Dr Boyd reported receiving grants from the National 
Institutes of Health during the conduct of the study; and other support from 
UpToDate outside the submitted work. Dr Choi reported receiving travel 
reimbursement from a Merck Foundation grant for a training session for Project 
ECHO. Dr Pollack reported receiving other support from Gilead Pharmaceuticals 
and personal fees from Open Communities Alliance outside the submitted work; and 
being an unpaid member of the health advisory committee for the nonprofit 
organization Enterprise Community Partners; and working part time on a temporary 
assignment assisting the US Department of Housing and Urban Development agency 
in its contract with Johns Hopkins University on housing and health issues. No 
other disclosures were reported.


576. Lung Cancer. 2020 Aug;146:42-49. doi: 10.1016/j.lungcan.2020.05.011. Epub
2020  May 28.

Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III 
non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness 
analysis.

Han J(1), Tian K(2), Yang J(1), Gong Y(3).

Author information:
(1)Department of Head and Neck Oncology and Department of Radiation Oncology, 
Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, 
Sichuan University, Chengdu 610041, PR China.
(2)Department of Urology, Institute of Urology, West China Hospital, Sichuan 
University, Chengdu 610041, PR China.
(3)Department of Thoracic Oncology and State Key Laboratory of Biotherapy, 
Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, 
PR China. Electronic address: gongyouling@hotmail.com.

INTRODUCTION: Recently updated three-year survival data from the PACIFIC trial 
showed that durvalumab consolidation therapy improved OS rates versus placebo 
for patients with unresectable stage III non-small cell lung cancer (NSCLC) 
after chemoradiotherapy. Considering the impact of the high cost of durvalumab, 
its cost-effectiveness should be updated to see if its cost-effectiveness has 
changed from the US payers' perspective.
METHODS: A comprehensive Markov model was used to evaluate mean lifetime costs 
and effectiveness of first-line durvalumab consolidation therapy versus placebo 
for patients with unresectable stage III NSCLC imputing updated survival and 
quality-of-life data from the PACIFIC trial. The main endpoints include total 
costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental 
cost-effectiveness ratios (ICERs). One-way, two-way, and probabilistic 
sensitivity analyses were conducted to access the uncertainty in the variables. 
We also considered durvalumab cost-effectiveness in the subgroups.
RESULTS: Durvalumab consolidation therapy resulted in additional 1.34 LYs and 
1.01 QALYs, resulting in an ICER of $138,920 per QALY versus the placebo 
treatment. One-way sensitivity analysis revealed that the utility values of two 
treatments, body weight, and unit cost of durvalumab have the greatest influence 
on the result. Subgroup analyses demonstrated that durvalumab was more cost 
effective for patients with non-squamous-cell lung cancer, followed by 25% or 
greater PD-L1 expression. Probabilistic sensitivity analysis showed that the 
probability of durvalumab being cost-effective versus the placebo is 62.6% at a 
willingness-to-pay (WTP) of $150,000 per QALY CONCLUSION: Our analyses 
demonstrated that receiving durvalumab consolidation therapy was more 
cost-effective than placebo at a WTP threshold of $150,000. These results can be 
of use to US practitioners in the application of durvalumab and for durvalumab 
prescription and reimbursement policies.

Copyright © 2020 Elsevier B.V. All rights reserved.

DOI: 10.1016/j.lungcan.2020.05.011
PMID: 32512272 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Competing Interest We wish to 
confirm that there are no known conflicts of interest associated with this 
publication and there has been no significant financial support for this work 
that could have influenced its outcome. We confirm that the manuscript has been 
read and approved by all named authors and that there are no other persons who 
satisfied the criteria for authorship but are not listed. We further confirm 
that the order of authors listed in the manuscript has been approved by all of 
us.


577. Turk J Med Sci. 2020 Dec 17;50(8):1838-1850. doi: 10.3906/sag-1912-205.

Survival analysis and factors affecting survival in patients who presented to 
the medical oncology unit with non-small cell lung cancer.

Önal Ö(1), Koçer M(2), Eroğlu HN(1), Yilmaz SD(1), Eroğlu I(3), Karadoğan D(4).

Author information:
(1)Department of Public Health, Faculty of Medicine, Süleyman Demirel 
University, Isparta, Turkey
(2)Department of Medical Oncology, Antalya Training and Research Hospital, 
Antalya, Turkey
(3)Department of Internal Medical Sciences, Faculty of Medicine, Süleyman 
Demirel University, Isparta, Turkey
(4)Department of Chest Diseases, Faculty of Medicine, Recep Tayyip Erdoğan 
University, Rize, Turkey

BACKGROUND/AIM: This study aimed to investigate the effect of clinical and 
pathological indicators at the time of the diagnosis on overall survival in 
patients recently diagnosed with non-small cell lung cancer.
MATERIALS AND METHODS: The study population consisted of patients who were 
diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University 
Hospital between January 1, 2010 and December 31, 2017 and presented to the 
medical oncology outpatient clinic.
RESULTS: A total of 518 patients were evaluated, including 260 patients with 
squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with 
non-small cell lung cancer-not otherwise specified, and 1 patient with large 
cell carcinoma. The average life expectancy was found to be 11.50 ± 1.40 months 
in patients with squamous cell carcinoma, 12.60 ± 1.59 months in patients with 
adenocarcinoma, and 8.70 ± 1.87 months in the other patients. The estimated 
5-year relative survival rate for non-small cell lung cancer was 8% (7% for men 
and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 
0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 
1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, 
HR, 1.57; P = 0.016, respectively), and the patient not having received 
radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were 
defined as statistically significant predictive factors that reduced the overall 
survival.
CONCLUSIONS: In this study, sex, stage, performance status, the presence of 
liver or bone metastases, and treatment had an effect on overall survival.

This work is licensed under a Creative Commons Attribution 4.0 International 
License.

DOI: 10.3906/sag-1912-205
PMCID: PMC7775717
PMID: 32512671 [Indexed for MEDLINE]

Conflict of interest statement: none declared


578. Int J Mol Sci. 2020 Jun 4;21(11):4031. doi: 10.3390/ijms21114031.

Tooth Formation: Are the Hardest Tissues of Human Body Hard to Regenerate?

Baranova J(1), Büchner D(2), Götz W(3), Schulze M(2), Tobiasch E(2).

Author information:
(1)Department of Biochemistry, Institute of Chemistry, University of São Paulo, 
Avenida Professor Lineu Prestes 748, Vila Universitária, São Paulo 05508-000, 
Brazil.
(2)Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied 
Sciences, von-Liebig-Straße 20, 53359 Rheinbach, NRW, Germany.
(3)Oral Biology Laboratory, Department of Orthodontics, Dental Hospital of the 
University of Bonn, Welschnonnenstraße 17, 53111 Bonn, NRW, Germany.

With increasing life expectancy, demands for dental tissue and whole-tooth 
regeneration are becoming more significant. Despite great progress in medicine, 
including regenerative therapies, the complex structure of dental tissues 
introduces several challenges to the field of regenerative dentistry. 
Interdisciplinary efforts from cellular biologists, material scientists, and 
clinical odontologists are being made to establish strategies and find the 
solutions for dental tissue regeneration and/or whole-tooth regeneration. In 
recent years, many significant discoveries were done regarding signaling 
pathways and factors shaping calcified tissue genesis, including those of tooth. 
Novel biocompatible scaffolds and polymer-based drug release systems are under 
development and may soon result in clinically applicable biomaterials with the 
potential to modulate signaling cascades involved in dental tissue genesis and 
regeneration. Approaches for whole-tooth regeneration utilizing adult stem 
cells, induced pluripotent stem cells, or tooth germ cells transplantation are 
emerging as promising alternatives to overcome existing in vitro tissue 
generation hurdles. In this interdisciplinary review, most recent advances in 
cellular signaling guiding dental tissue genesis, novel functionalized scaffolds 
and drug release material, various odontogenic cell sources, and methods for 
tooth regeneration are discussed thus providing a multi-faceted, up-to-date, and 
illustrative overview on the tooth regeneration matter, alongside hints for 
future directions in the challenging field of regenerative dentistry.

DOI: 10.3390/ijms21114031
PMCID: PMC7312198
PMID: 32512908 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest. The 
funders had no role in the design of the study; in the collection, analyses, or 
interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results.


579. J Hematol Oncol. 2020 Jun 8;13(1):72. doi: 10.1186/s13045-020-00908-z.

The global burden and attributable risk factor analysis of acute myeloid 
leukemia in 195 countries and territories from 1990 to 2017: estimates based on 
the global burden of disease study 2017.

Yi M(1), Li A(2), Zhou L(3), Chu Q(1), Song Y(2), Wu K(4)(5).

Author information:
(1)Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong 
University of Science and Technology, Wuhan, 430030, China.
(2)The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer 
Hospital, Zhengzhou, 450008, China.
(3)Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
University, Xi'an, 710004, China.
(4)Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong 
University of Science and Technology, Wuhan, 430030, China. wukm_lab@163.com.
(5)The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer 
Hospital, Zhengzhou, 450008, China. wukm_lab@163.com.

BACKGROUND: Acute myeloid leukemia (AML) is a common leukemia subtype and has a 
poor prognosis. The risk of AML is highly related to age. In the context of 
population aging, a comprehensive report presenting epidemiological trends of 
AML is evaluable for policy-marker to allocate healthy resources.
METHODS: This study was based on the Global Burden of Disease 2017 database. We 
analyzed the change trends of incidence rate, death rate, and 
disability-adjusted life year (DALY) rate by calculating the corresponding 
estimated annual percentage change (EAPC) values. Besides, we investigated the 
influence of social development degree on AML's epidemiological trends and 
potential risk factors for AML-related mortality.
RESULTS: From 1990 to 2017, the incidence of AML gradually increased in the 
globe. Males and elder people had a higher possibility to develop AML. Developed 
countries tended to have higher age-standardized incidence rate and death rate 
than developing regions. Smoking, high body mass index, occupational exposure to 
benzene, and formaldehyde were the main risk factors for AML-related mortality. 
Notably, the contribution ratio of exposure to carcinogens was significantly 
increased in the low social-demographic index (SDI) region than in the high SDI 
region.
CONCLUSION: Generally, the burden of AML became heavier during the past 28 years 
which might need more health resources to resolve this population 
aging-associated problem. In the present stage, developed countries with high 
SDI had the most AML incidences and deaths. At the same time, developing 
countries with middle- or low-middle SDI also need to take actions to relieve 
rapidly increased AML burden.

DOI: 10.1186/s13045-020-00908-z
PMCID: PMC7282046
PMID: 32513227 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare that they have no competing 
interests.


580. Public Health Nutr. 2020 Aug;23(11):1907-1915. doi:
10.1017/S1368980019004828.  Epub 2020 Jun 9.

Trends in BMI among elderly Japanese population: findings from 1973 to 2016 
Japan National Health and Nutrition Survey.

Tarui I(1), Okada E(1), Okada C(1), Saito A(1), Takimoto H(1).

Author information:
(1)Department of Nutritional Epidemiology and Shokuiku, National Institutes of 
Biomedical Innovation, Health and Nutrition, Tokyo162-8636, Japan.

OBJECTIVE: To examine 44-year trends in height, weight and BMI, and the 
prevalence of overweight/obesity and underweight in the elderly Japanese 
population because Japan, the country with the longest life expectancy, has the 
highest ageing population.
DESIGN: Using the nationally representative cumulative data from the Japan 
National Health and Nutrition Survey 1973-2016, sex-specific and age-adjusted 
mean height, weight and BMI, and the prevalence of overweight/obesity and 
underweight were calculated for each year. Trend analyses were performed using 
the Joinpoint Regression Program. Next, changes in height, weight and BMI, and 
the prevalence of overweight/obesity and underweight were estimated for each age 
group (65-69, 70-79 and >80 years) according to the birth year groups.
SETTING: Japan.
PARTICIPANTS: Individuals aged ≥65 years with complete data on height and body 
weight measurements (N 94 508).
RESULTS: Trends in average height and weight increased over the four decades in 
both men and women. The prevalence of overweight/obesity dramatically increased 
and nearly tripled in men, accompanied with significantly decreased underweight 
prevalence. Furthermore, the increasing trend in average BMI and 
overweight/obesity prevalence in women reached a peak in 2002 and showed a 
decreasing trend thereafter, while a downward trend in underweight prevalence 
showed a gradual increase in women since 2003.
CONCLUSIONS: Trends in height, weight and BMI among the elderly population 
should continue to be closely monitored in parallel with the effects of dietary 
changes, energy intake and physical activity (step counts).

DOI: 10.1017/S1368980019004828
PMCID: PMC10200467
PMID: 32513347 [Indexed for MEDLINE]


581. Semin Oncol. 2020 Apr-Jun;47(2-3):138-143. doi: 
10.1053/j.seminoncol.2020.04.006. Epub 2020 May 28.

Optimizing the treatment algorithm for sentinel lymph node mapping in 
endometrial cancer.

Pijnenborg JMA(1), Reijnen C(2), Vergeldt TFM(3), Zusterzeel PLM(3).

Author information:
(1)Department of Obstetrics and Gynaecology, Radboud University Medical Center, 
Nijmegen, the Netherlands. Electronic address: 
Hanny.MA.Pijnenborg@radboudumc.nl.
(2)Department of Obstetrics and Gynaecology, Radboud University Medical Center, 
Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, 
Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
(3)Department of Obstetrics and Gynaecology, Radboud University Medical Center, 
Nijmegen, the Netherlands.

The incidence of endometrial cancer, the most common gynecological malignancy, 
is increasing as life expectancy and obesity both rise. Lymph node status is the 
most important predictor for outcome, yet routine lymphadenectomy does not 
confer a survival benefit and is associated with substantial surgical morbidity. 
In the last decade, sentinel lymph node (SLN) mapping has emerged as a feasible 
and accurate alternative to full lymphadenectomy. Yet, SLN has introduced a 
distinction between micro- and macrometastasis, and the entity of non-SLN 
involvement with their attendant impact on outcome. Included among the raised 
issues is the question of whether positive sentinel nodes should be followed by 
pelvic and/or para-aortic lymphadenectomy dependent on the presence of 
macrometastasis at frozen section or other criteria. Moreover, the proper 
adjuvant treatment for individual cases with micrometastasis and/or isolated 
tumor cells is unclear. Recently published data on this topic are summarized in 
order to optimize the current treatment algorithm as it relates to the results 
of SLN assessment in endometrial cancer.

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

DOI: 10.1053/j.seminoncol.2020.04.006
PMID: 32513418 [Indexed for MEDLINE]


582. Bull World Health Organ. 2020 May 1;98(5):353-359. doi:
10.2471/BLT.19.239616.  Epub 2020 Mar 9.

The evolution of community-based primary health care, Slovenia.

Johansen AS(1), Vracko P(2), West R(1).

Author information:
(1)World Health Organization European Centre for Primary Health Care, Kazakh 
National Medical University, 88 Tole Bi Street, Almaty, 050012 Kazakhstan.
(2)National Institute of Public Health of the Republic of Slovenia, Ljubljana, 
Slovenia.

PROBLEM: Slovenia's model of primary health care relied on reactive, episodic 
care and was ill-equipped to address the country's burden of disease dominated 
by noncommunicable diseases.
APPROACH: The government has developed a multidisciplinary, community-based, 
prevention-oriented service delivery model for primary health care. A compulsory 
family medicine residency programme was introduced in 2000, and from 2004 
screening and control of chronic diseases were established in family medicine 
practices. Health promotion centres were established, providing group 
interventions to support healthy lifestyles. After 2011, registered nurses were 
introduced to conduct screening for chronic diseases, provide counselling and 
manage patients with stable noncommunicable diseases.
LOCAL SETTING: In 1992, the government transformed Slovenia's health financing 
scheme to a social insurance system based on mandatory payroll taxes. The system 
enabled private provision of health services, although primary care was mostly 
provided by publicly funded community health centres. A strong gatekeeping role 
was introduced.
RELEVANT CHANGES: Despite spending less on health than the European Union (EU) 
average, by 2013 Slovenia's life expectancy was higher than the average for EU 
countries. The increase was due in part to rapidly declining infant and 
under-five mortality and a faster decline in premature mortality due to chronic 
diseases.
LESSONS LEARNT: Slovenia's approach was enabled by strong public health and 
governance structures, along with accountability mechanisms that monitored 
outcomes and took corrective action when necessary. New programmes were piloted, 
creating a strong evidence base that facilitated obtaining sustainable 
financing, while national roll-out was supported by regional branches of the 
National Institute of Public Health.

Publisher: PROBLÈME: Le modèle slovène de soins de santé primaires reposait sur 
une prise en charge épisodique et réactive. En outre, il n'était pas équipé pour 
faire face au fardeau des maladies du pays, dominé par des affections non 
transmissibles.
APPROCHE: Le gouvernement a développé un modèle de prestation de services 
multidisciplinaire, communautaire et axé sur la prévention pour les soins de 
santé primaires. Un programme obligatoire de résidence en médecine familiale a 
été instauré en 2000 et, à partir de 2004, un système de dépistage et de suivi 
des maladies chroniques a été mis en place dans les cabinets de médecine 
familiale. Des centres de promotion de la santé ont été créés afin d'effectuer 
des interventions de groupe destinées à encourager l'adoption d'un mode de vie 
sain. Dès 2011, des infirmières agréées ont été chargées de mener des actions de 
dépistage des maladies chroniques, de fournir des conseils et de gérer les 
patients présentant des affections non transmissibles stables.
ENVIRONNEMENT LOCAL: En 1992, le gouvernement a transformé le régime slovène de 
financement de la santé en système d'assurance sociale basé sur des taxes 
obligatoires prélevées sur les salaires. Ce système a entraîné l'apparition de 
prestations privées de services de santé, bien que les soins primaires soient 
principalement prodigués par des centres de santé communautaires financés par 
l'État. Une fonction de contrôle efficace a été établie.
CHANGEMENTS SIGNIFICATIFS: Malgré des dépenses en soins de santé inférieures à 
la moyenne de l'Union européenne (UE), l'espérance de vie slovène en 2013 était 
plus élevée que celle observée dans les autres pays de l'UE. Cette augmentation 
s'expliquait en partie par une diminution rapide de la mortalité chez les 
nourrissons et les enfants de moins de cinq ans, ainsi que par une accélération 
de la baisse des décès prématurés liés à des maladies chroniques.
LEÇONS TIRÉES: L'approche de la Slovénie a été rendue possible par de solides 
structures de gouvernance et de santé publique, mais aussi par des mécanismes de 
responsabilité qui ont suivi les résultats et pris des mesures correctives le 
cas échéant. De nouveaux programmes ont été testés et ont engendré une base 
factuelle stable qui a facilité l'obtention de financements durables, tandis que 
le déploiement à l'échelle nationale a reçu le soutien des antennes régionales 
de l'Institut national de santé publique.

Publisher: SITUACIÓN: El modelo de atención primaria de la salud de Eslovenia se 
basaba en el cuidado paliativo y episódico, y no estaba bien equipado para 
atender a todas las enfermedades del país, que eran en su mayoría enfermedades 
no transmisibles.
ENFOQUE: El Gobierno ha elaborado un modelo de prestación de servicios 
multidisciplinarios, comunitarios y orientados a la prevención para la atención 
primaria de la salud. En 2000, se adoptó un programa de residencia obligatorio 
en medicina familiar y, a partir de 2004, se estableció un programa de detección 
y de control de las enfermedades crónicas en los consultorios de medicina 
familiar. Se establecieron centros de promoción de la salud, en los que se 
realizan intervenciones en grupo para apoyar estilos de vida saludables. A 
partir de 2011, se introdujeron enfermeras tituladas para realizar exámenes de 
detección de enfermedades crónicas, prestar asesoramiento y atender a pacientes 
con enfermedades estables no transmisibles.
MARCO REGIONAL: En 1992, el Gobierno transformó el plan de financiamiento de la 
salud de Eslovenia en un sistema de seguro social basado en impuestos 
obligatorios sobre las nóminas. El sistema permitía la prestación privada de 
servicios sanitarios, aunque la atención primaria se prestaba principalmente en 
centros de salud comunitarios que se financiaban con fondos públicos. Además, se 
adoptó una función importante de control de acceso.
CAMBIOS IMPORTANTES: Aunque el gasto en salud es inferior en comparación con la 
media de la Unión Europea (UE), en 2013, la esperanza de vida de Eslovenia era 
superior a la media de los países de la UE. El incremento se debió en parte a la 
reducción rápida de la mortalidad de infantes y de niños menores de cinco años y 
a una disminución más rápida de la mortalidad prematura por enfermedades 
crónicas.
LECCIONES APRENDIDAS: El enfoque de Eslovenia fue posible gracias a las 
estructuras sólidas de salud pública y de gobernanza, junto con los mecanismos 
de rendición de cuentas que supervisaban los resultados y adoptaban medidas 
correctivas cuando era necesario. Se probaron nuevos programas, lo que creó una 
base de evidencia sólida que facilitó la obtención de un financiamiento 
sostenible, mientras que las filiales regionales del Instituto Nacional de Salud 
Pública apoyaron la puesta en marcha a nivel nacional.

Publisher: المشكلة اعتمد نموذج الرعاية الصحية الأولية في سلوفينيا على الرعاية 
التفاعلية والعرضية، كما كان هذا النموذج غير مجهز لمواجهة عبء الأمراض في الدولة 
والذي يخضع لسيطرة الأمراض غير المعدية. الأسلوب قامت الحكومة بتطوير نموذج رعاية 
صحية أولية لتقديم الخدمات يتميز بتعدد التخصصات، والاعتماد على المجتمع، ويكون 
موجهًا نحو الوقاية. تم تقديم برنامج إلزامي لطب الأسرة في عام 2000، ومنذ عام 2004 
تم إدخال برنامج الفحص والسيطرة على الأمراض المزمنة إلى ممارسات طب الأسرة. كما تم 
إنشاء مراكز لتعزيز الصحة، والتي توفر التدخلات الجماعية لدعم أنماط الحياة الصحية. 
بعد عام 2011، تم الاستعانة بالممرضات المسجلات لإجراء فحص للأمراض المزمنة، وتقديم 
المشورة وإدارة المرضى الذين يعانون من أمراض غير معدية مستقرة. المواقع المحلية في 
عام 1992، قامت الحكومة بتحويل مخطط التمويل الصحي في سلوفينيا إلى نظام للتأمين 
الاجتماعي قائم على الضرائب الإجبارية على الرواتب. أتاح النظام فرصة توفير الخدمات 
الصحية الخاصة، على الرغم من أن الرعاية الصحية الأولية تم توفيرها في الغالب من 
جانب مراكز الصحة المجتمعية الممولة من القطاع العام. كذلك ظهر دور قوي للبوابات 
الإعلامية. التغيّرات ذات الصلة على الرغم من الإنفاق على الصحة بشكل أقل من متوسط 
الاتحاد الأوروبي (EU)، إلا أن متوسط العمر المتوقع في سلوفينيا في عام 2013 كان 
أعلى من المتوسط في دول الاتحاد الأوروبي. وكانت الزيادة ترجع بشكل جزئي إلى 
الانخفاض السريع في معدل وفيات الرضع والأطفال تحت سن الخامسة، وتراجع بشكل أسرع في 
معدل الوفيات المبكرة بسبب الأمراض المزمنة. الدروس المستفادة تم دعم المنهج الذي 
اتبعته سلوفينيا بواسطة هياكل صحية قوية سواء عامة أو حوكمية، إلى جانب آليات 
المساءلة التي تراقب النتائج وتتخذ إجراءً تصحيحياً عند الضرورة. تم إطلاق برامج 
الجديدة، مما أدى إلى إنشاء قاعدة أدلة قوية سهلت الحصول على تمويل مستدام، كما تم 
دعم التنفيذ الوطني بواسطة الفروع الإقليمية للمعهد الوطني للصحة العامة.

Publisher: 问题: 斯洛文尼亚的初级医疗护理模式依赖于被动型、不连贯的护理并且无法充分解决该国由非传染性疾病占主导地位的疾病负担。.
方法: 政府为初级医疗护理制定了多学科、基于社区、以预防为主的服务提供模式。自 2000 年开始实施了一项强制性的家庭医学住院医师培训计划，并且从 2004 
年起在家庭医学实践中对慢性病进行筛查和控制。建立了健康促进中心，提供团体干预以支持健康的生活方式。自 2011 
年之后，引进了注册护士对慢性病进行筛查，提供咨询并管理患有稳定非传染性疾病的患者。.
当地状况: 政府于 1992 
年将斯洛文尼亚的医疗融资方案转变为基于强制性工资税的社会保险体系。尽管主要由公立社区医疗中心提供初级医疗，但该体系推动了私营医疗服务。发挥了强大的首诊作用。.
相关变化: 虽然斯洛文尼亚的医疗支出低于欧盟 (EU) 平均水平，但截至 2013 
年，斯洛文尼亚的预期寿命却高于欧盟国家的平均寿命。增长的部分原因是婴儿和五岁以下儿童的死亡率迅速下降以及因慢性病导致的过早死亡率下降更快。.
经验教训: 
斯洛文尼亚的做法得以推动的原因在于强大的公共医疗和治理结构，以及负责监控效果并在必要时采取纠正措施的问责机制。试行了新的计划，以强有力的证据为基础，有助于获得可持续融资，而全国范围内的推广则得到了国家公共医疗研究院地区分支机构的支持。.

Publisher: ПРОБЛЕМА: Модель первичного медико-санитарного обслуживания в 
Словении опиралась на эпизодическое обслуживание в качестве ответных мер и не 
справлялась с бременем болезней в стране, где преобладают неинфекционные 
заболевания.
ПОДХОД: Правительство разработало междисциплинарную, ориентированную на 
профилактику модель предоставления первичного медико-санитарного обслуживания на 
уровне общины. В 2000 году была введена обязательная программа семейной медицины 
по месту жительства, а с 2004 года в практику семейной медицины были введены 
скрининговое обследование и мониторинг хронических заболеваний. Были созданы 
центры охраны здоровья, обеспечивающие групповые мероприятия для поддержки 
здорового образа жизни. Начиная с 2011 года проведение скрининговых обследований 
на наличие хронических заболеваний и консультаций, а также ведение пациентов со 
стабильным состоянием неинфекционных заболеваний осуществляются специальным 
дипломированным медицинским персоналом.
МЕСТНЫЕ УСЛОВИЯ: В 1992 году правительство Словении преобразовало систему 
финансирования здравоохранения в систему социального страхования, основанную на 
обязательных налогах на заработную плату. Система позволила обеспечить частное 
предоставление медицинских услуг, хотя первичное медико-санитарное обслуживание 
в основном оказывалось общественными медицинскими центрами, финансируемыми 
государством. Была введена роль строгого куратора.
ОСУЩЕСТВЛЕННЫЕ ПЕРЕМЕНЫ: Несмотря на меньшие расходы на здравоохранение, чем в 
среднем по Европейскому союзу (ЕС), к 2013 году ожидаемая продолжительность 
жизни в Словении была выше, чем в среднем по странам ЕС. Такое увеличение было 
отчасти обусловлено стремительным снижением младенческой и детской смертности в 
возрасте до пяти лет и более быстрыми темпами снижения преждевременной 
смертности от хронических заболеваний.
ВЫВОДЫ: Подход Словении оказался выполним благодаря наличию надежных структур 
общественного здравоохранения и государственного управления, а также механизмам 
подотчетности, которые позволяли отслеживать результаты и принимать 
корректирующие меры при необходимости. Внедрялись новые программы, создающие 
прочную базу фактических данных, которая способствовала получению устойчивого 
финансирования, в то время как введение системы в действие в рамках всего 
государства поддерживалось региональными отделениями Национального института 
общественного здравоохранения.

(c) 2020 The authors; licensee World Health Organization.

DOI: 10.2471/BLT.19.239616
PMCID: PMC7265942
PMID: 32514200 [Indexed for MEDLINE]


583. Contemp Oncol (Pozn). 2020;24(1):13-16. doi: 10.5114/wo.2020.93680. Epub
2020  Mar 13.

Burden of cancer in Poland analysed using potential years of life lost.

Orlewska K(1), Stępień R(2), Orlewska E(2).

Author information:
(1)First Faculty of Medicine, Medical University of Warsaw, Poland.
(2)Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, 
Poland.

AIM OF THE STUDY: The aim was to assess the impact of the most frequent 
cancer-related causes of death in Poland by estimating the years of potential 
life lost (YPLL) and to compare different measures of the burden of cancer 
deaths on the population.
MATERIAL AND METHODS: Mortality rate, YPLL and mean YPLL were calculated for the 
11 most frequently recorded cancer-related causes of death in Poland. YPLL were 
measured applying the up-to-date reference life tables proposed by the Institute 
for Health Metrics and Evaluation and used in the Global Burden of Disease study 
(GBD 2015). Absolute numbers of cancer deaths by site, gender and five-year age 
groups were obtained from the Polish National Cancer Registry (2015).
RESULTS: In 2015 the total YPLL amounted to 1,990,457, with 23.6% from lung and 
bronchial cancer. Mean YPLL was 19.79 years and varied considerably according to 
tumour site (26.12 [brain] - 14.3 [prostate]). Three tumour sites (brain, 
ovarian and kidney) are positioned higher according to mean YPLL than according 
to YPLL percentage and mortality percentage.
CONCLUSIONS: Our results draw attention to the impact of cancer on society and 
individual patients. Addressing research efforts to prevention and/or treatment 
of major YPLL causes could result in a substantial impact on general life 
expectancy.

Copyright: © 2020 Termedia Sp. z o. o.

DOI: 10.5114/wo.2020.93680
PMCID: PMC7265957
PMID: 32514233

Conflict of interest statement: The authors declare no conflict of interest.


584. Eur Cardiol. 2020 May 18;15:e48. doi: 10.15420/ecr.2020.14. eCollection 2020
 Feb.

Ethical Issues in Decision-making Regarding the Elderly Affected by Coronavirus 
Disease 2019: An Expert Opinion.

Martínez-Sellés D(1), Martínez-Sellés H(2), Martinez-Sellés M(2)(3).

Author information:
(1)School of Medicine, Autonomous University of Barcelona Barcelona, Spain.
(2)School of Medicine, Complutense University of Madrid Madrid, Spain.
(3)Cardiology Department, Gregorio Marañón University Hospital, CIBERCV, 
European University of Madrid Madrid, Spain.

The coronavirus disease 2019 (COVID-19) pandemic is resulting in ethical 
decisions regarding resource allocation. Prioritisation reflects established 
practices that regulate the distribution of finite resources when demand exceeds 
supply. However, discrimination based on sex, race or age has no role in 
prioritisation unless clearly justified. The risk posed by COVID-19 is higher 
for elderly people than for younger people, so older adults should be 
prioritised in preventive measures. In the case of people who already have 
COVID-19, healthcare professionals might prioritise those most likely to 
survive. Making decisions based on chronological age alone is not justified; in 
addition to age, other aspects that determine theoretical life expectancy must 
be taken into account. Individualised correct prioritisation in the allocation 
of scarce resources is essential to good clinical practice.

Copyright © 2020, Radcliffe Cardiology.

DOI: 10.15420/ecr.2020.14
PMCID: PMC7265102
PMID: 32514316

Conflict of interest statement: Disclosure: The authors have no conflicts of 
interest to declare.


585. Clin Res Cardiol. 2021 May;110(5):711-724. doi: 10.1007/s00392-020-01685-y.
Epub  2020 Jun 8.

Myocardial salvage is increased after sympathetic renal denervation in a pig 
model of acute infarction.

Pastormerlo LE(1)(2)(3), Burchielli S(4), Ciardetti M(4), Aquaro GD(4), 
Grigoratos C(4)(5), Castiglione V(5), Pucci A(6), Franzini M(6), Giorgetti A(4), 
Marzullo P(4), Benelli E(4), Masotti S(4), Musetti V(4), Bernini F(5), Berti 
S(4), Passino C(4)(5), Emdin M(4)(5).

Author information:
(1)Fondazione G. Monasterio CNR-Regione Toscana, Massa, Pisa, Italy. 
pastormerlo@ftgm.it.
(2)Life Sciences Institute, Scuola Superiore Sant'Anna, Pisa, Italy. 
pastormerlo@ftgm.it.
(3)Division of Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio 
CNR-Regione Toscana, Via Giuseppe Moruzzi 1, 56124, Pisa, Italy. 
pastormerlo@ftgm.it.
(4)Fondazione G. Monasterio CNR-Regione Toscana, Massa, Pisa, Italy.
(5)Life Sciences Institute, Scuola Superiore Sant'Anna, Pisa, Italy.
(6)Institute of Clinical Pathology, University of Pisa, Pisa, Italy.

RATIONALE: Despite advances in treatment of acute myocardial infarction (AMI), 
many patients suffer significant myocardial damage with cardiac dysfunction. 
Sympathetic renal denervation (RD) may reduce adrenergic activation following 
AMI.
OBJECTIVE: To investigate the potential role of RD limiting myocardial damage 
and remodeling when performed immediately after AMI.
METHODS AND RESULTS: Sixteen farm pigs underwent 90 min left anterior descending 
artery balloon occlusion. Eight pigs underwent RD immediately after reperfusion. 
LV function, extent of myocardium at risk, and myocardial necrosis were 
quantified by cardiac magnetic resonance 5 and 30 days after AMI. 123I-MIBG 
scintigraphy was performed 31 days after AMI to image myocardial sympathetic 
innervation. Heart norepinephrine was quantified (from necrotic, border and 
remote zone). RD and control did not differ in myocardium at risk extent (59 ± 9 
vs 55 ± 11% of LV mass) at 5 days. At 30 days CMR, RD pigs had smaller necrotic 
areas than control as assessed by gadolinium delay enhancement (18 ± 7 vs 
30 ± 12% of LV mass, p = 0.021) resulting in improved myocardial salvage index 
(60 ± 11 vs 44 ± 27%, p < 0.001). RD pigs had higher cardiac output (3.7 ± 0.8 
vs 2.66 ± 0.7 L/min, p < 0.001) and lower LV end diastolic volume (98 ± 16 vs 
113 ± 31 ml, p = 0.041). 123I-MIBG defect extension was smaller in RD than 
control (60 ± 28 vs 78 ± 17%, p < 0.05) with significant reduction in the 
difference between innervation and perfusion defects (25 ± 12 vs 36 ± 30%, 
p = 0.013). NE content from necrotic area (238; IQR 464 vs 2546; IQR 1727 ng/g 
in RD and control, respectively, p < 0.001) and from border zone (295; IQR 264 
vs 837; IQR 207 in RD and control, respectively, p = 0.031) was significantly 
lower in RD than control.
CONCLUSIONS: RD results in increased myocardial salvage and better cardiac 
function, when performed immediately after AMI. Reduction of sympathetic 
activation with preservation of cardiac sympathetic functionality warranted by 
RD may sustain these effects.

DOI: 10.1007/s00392-020-01685-y
PMID: 32514602 [Indexed for MEDLINE]


586. Pharmacoeconomics. 2020 Oct;38(10):1043-1053. doi:
10.1007/s40273-020-00932-4.

Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut 
Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE 
Single Technology Appraisal.

Wijnen B(1)(2), Armstrong N(3), Ramaekers B(4), Witlox W(4), Westwood M(3), 
Fayter D(3), Ryder S(3), Buksnys T(3), Worthy G(3), Misso K(3), Grimm S(4), 
Kleijnen J(3), Joore M(4)(5).

Author information:
(1)Department of Clinical Epidemiology and Medical Technology Assessment, 
Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, 
The Netherlands. bwijnen@trimbos.nl.
(2)Centre of Economic Evaluation, Trimbos Institute (Netherlands Institute of 
Mental Health and Addiction), Utrecht, The Netherlands. bwijnen@trimbos.nl.
(3)Kleijnen Systematic Reviews Ltd, York, UK.
(4)Department of Clinical Epidemiology and Medical Technology Assessment, 
Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, 
The Netherlands.
(5)Care and Public Health Research Institute (CAPHRI), Maastricht University, 
Maastricht, The Netherlands.

GW Research Ltd. provided two separate, but similar, submissions to the National 
Institute for Health and Care Excellence (NICE) on the clinical and 
cost-effectiveness of cannabidiol (CBD) 10 mg/kg/day, trade name Epidyolex®, for 
the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome 
(LGS) and Dravet syndrome (DS). This paper highlights important methodological 
issues related to the company submissions, the Evidence Review Group (ERG) 
reports, and the subsequent development of the NICE guidance by the Appraisal 
Committee (AC) for the use of CBD. The company identified four randomised 
controlled trials (RCTs) of CBD (GWPCARE1 and GWPCARE2 for DS, and GWPCARE3 and 
GWPCARE4 for LGS) and an ongoing open-label extension study (GWPCARE5) as 
relevant to both submissions. In these RCTs, CBD in addition to current clinical 
management (CCM) was compared to CCM without CBD (i.e. CCM plus placebo). 
GWPCARE2 and GWPCARE3 were three-arm studies and compared two dosages of CBD 
(10 mg/kg/day and 20 mg/kg/day) in addition to CCM and CCM plus placebo. 
GWPCARE1 and GWPCARE4 compared CBD (20 mg/kg/day) in addition to CCM and CCM 
plus placebo. Both DS patients in GWPCARE2 and LGS patients in GWPCARE3 who 
received 10 mg/kg/day CBD in addition to CCM achieved better seizure frequency 
outcomes than those who received CCM plus placebo. In the company's base case, 
use of CBD for LGS patients resulted in an incremental cost-effectiveness ratio 
(ICER) of £31,107 per quality-adjusted life year (QALY) gained and, for DS 
patients, £36,046 per QALY gained versus CCM. The ERG considered that these 
ICERs were extremely uncertain and suffered from validity issues concerning 
model structure (e.g. patients receiving CCM moved back to baseline drop seizure 
frequency), input (e.g. inclusion of caregivers' QALYs), and transparency issues 
(e.g. hidden worksheets and coding in Visual Basic for Applications), and hence 
incorporated adjustments to the original base case which increased the ICERs. 
During the process, the European Medicines Agency (EMA) licence granted 
marketing authorisation for CBD only in conjunction with clobazam. Hence, the 
company provided evidence from this subgroup in an additional submission, which 
resulted in an ICER of £33,721 per QALY gained for LGS and an ICER of £32,471 
per QALY gained for DS. In this submission and clarifications, the ERG was able 
to verify and validate most of the company's responses to the ERG's concerns. 
However, some issues remained regarding the face validity of model assumptions 
on patient pathways after treatment discontinuation. Finally, the AC recommended 
CBD with clobazam as an option for treating seizures associated with LGS and DS 
in patients aged 2 years and older only if (1) the frequency of drop seizures is 
checked every 6 months and CBD is stopped if the frequency has not fallen by at 
least 30% compared with 6 months before starting treatment and (2) the company 
provides CBD according to the commercial arrangement.

DOI: 10.1007/s40273-020-00932-4
PMID: 32514751 [Indexed for MEDLINE]


587. Ann Surg Oncol. 2021 Feb;28(2):1069-1078. doi: 10.1245/s10434-020-08679-0.
Epub  2020 Jun 8.

A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic 
Carcinoma: An International Delphi Survey.

Cherkaoui Z(1)(2)(3), González C(1)(2), Wakabayashi T(4), Delattre B(5), Léost 
E(5), Serra S(6), Huppertz J(6), Klein F(2), Stéphan M(2), Meyer JM(7), Schaff 
A(2), Martinis E(2), Bangoura E(2), Kieffer S(2), Blanès S(2), Haddad E(8), De 
Guio G(9), Felli E(2), Pernot S(1), Marescaux J(1)(4), Mutter D(1)(2)(4), Lugiez 
C(5), Pessaux P(10)(11)(12)(13)(14); IHU-VBHC Working Group.

Collaborators: Amaral P, Anthony C, Araujo R, Asbun H, Atkinson S, Bangoura E, 
Bataille MP, Bertens K, Blanès S, Briceno J, Carsten Palnaes H, Catalina Mursch 
M, Cesari-Loussouarn C, Cherkaoui Z, Coburn N, Colin F, Conrad C, Cordelier V, 
Crews F, De Blasi V, Deguio G, Delattre B, Demartines N, Dengsø K, Doherty M, 
Fernandez E, Fuks D, Gil A, Goldbarg V, González C, Haddad E, Hallet J, Hausser 
N, Hernandez R, Herrscher H, Higuchi R, Hillingsø J, Hody P, Horn P, Huppertz J, 
Ikari N, Izumo W, Jacky E, Jayaraman S, Jenner R, Jeune F, Kaneko H, Kato T, 
Khanna S, Kieffer S, Klein F, Kurtz JE, Law C, Lazarus L, Lekeir M, Léost E, 
Lemos B, Lima L, Lugiez C, Lux B, Machado G, Marescaux J, Martel G, Marthey L, 
Martí-Cruchaga P, Martinis E, Memeo R, Meyer JM, Munk Plum L, Munoz C, Mutter D, 
Nanji S, O'connor A, Omori A, Osorio P, Panaro F, Pardo F, Pereira LL, Perez P, 
Pernot S, Pessaux P, Quijano Y, Ramallo M, Regenet N, Resende A, Rotellar F, Sa 
Cunha A, Sanchez Claria R, Santana D, Santana R, Schaff A, Schwarz L, Segedi M, 
Serra S, Serrano P, Shiihara M, Soubrane O, Stéphan M, Takeshita N, Torres O, 
Tsang M, Turrini O, Uemura S, Valle E, Van Osch A, Vicente E, Vincent A, 
Wakabayashi G, Wakabayashi T, Weiss H, Yamamoto M, Yamashita S, Yazawa T, 
Zacharias T.

Author information:
(1)Institute of Image-Guided Surgery (IHU Strasbourg), Université de Strasbourg, 
Strasbourg, France.
(2)Digestive and Endocrine Surgery Unit, Nouvel Hôpital Civil, Hôpitaux 
Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
(3)SSPC (Simplification of Surgical Patient Care), UR UPJV 7518, University of 
Picardie Jules Verne, Amiens, France.
(4)Research Institute Against Digestive Cancer (IRCAD), Strasbourg, France.
(5)Integrated Health Solutions (IHS), Medtronic France, Boulogne-Billancourt, 
France.
(6)Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, 
France.
(7)CISS Alsace (Collectif Inter Associatif Sur la Santé), Strasbourg, France.
(8)Oncology Unit, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 
Strasbourg, France.
(9)Groupe Hospitalier Saint Vincent, Strasbourg, France.
(10)Institute of Image-Guided Surgery (IHU Strasbourg), Université de 
Strasbourg, Strasbourg, France. patrick.pessaux@chru-strasbourg.fr.
(11)Digestive and Endocrine Surgery Unit, Nouvel Hôpital Civil, Hôpitaux 
Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France. 
patrick.pessaux@chru-strasbourg.fr.
(12)Research Institute Against Digestive Cancer (IRCAD), Strasbourg, France. 
patrick.pessaux@chru-strasbourg.fr.
(13)Hepatobiliary and Pancreatic Surgical Unit, Nouvel Hôpital Civil (NHC), 
Strasbourg, France. patrick.pessaux@chru-strasbourg.fr.
(14)Unité Inserm UMR_S1110, Institut de Recherche sur les Maladies Virales et 
Hépatiques, Strasbourg, France. patrick.pessaux@chru-strasbourg.fr.

BACKGROUND: Global health systems are shifting toward value-based health care to 
improve patient outcomes in the face of rising health care costs. The challenge 
is to identify standardized outcome measurements that allow optimal 
quality-of-care monitoring and comparison to optimize medical practices and 
patient pathways. A common outcomes definition is required, including medical 
results (Clinical Reported Outcomes Measurements [CROMs]) and quality-of-life 
components that matter most to patients (Patient-Reported Outcomes Measurements 
[PROMs]), which are particularly important for severe pathologies with short 
life expectancy such as pancreatic cancer. This study aimed to create 
standardized metrics that could be used for outcomes analysis of pancreatic 
cancer care.
METHODS: A multidisciplinary working group (WG) was assembled. A systematic 
review was performed to collect the most used outcomes in clinical studies of 
pancreatic cancers. The study reviewed 570 studies published in the last 
10 years. From these studies, 3370 outcomes, including CROMs, and PROMs, were 
listed and prioritized. The WG reached a consensus on key outcomes, proposed 
groupings for CROMs and PROMs, identified existing questionnaires that could be 
used for PROMs collection, and set the timeline for data collection. To refine 
and validate the final outcomes set, an international external committee 
completed a Delphi process (two rounds for both CROMS and PROMs).
RESULTS: After the systematic literature review, the WG selected 102 outcomes 
(92 CROMs and 10 PROMs) for submission to the international Delphi vote 
committee. The committee retrained 89 outcomes (78 CROMs and 11 PROMs). For the 
PROMs, the WG and the international external committee chose a validated 
questionnaire, the Functional Assessment of Cancer Therapy-Hepatobiliary, which 
covers all of the 11 selected PROMs.
CONCLUSIONS: A standardized set of outcome measures that need to be validated 
through international health outcome comparisons and quality-of-care assessments 
was built. Pilot projects are underway to test and optimize the approach in 
real-life conditions.

DOI: 10.1245/s10434-020-08679-0
PMID: 32514806 [Indexed for MEDLINE]


588. Spine (Phila Pa 1976). 2020 Oct 1;45(19):1383-1385. doi: 
